FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to gastroenterology and hepatology. Blood serum is analyzed, as well as bioimpedance analysis of human body composition, anthropometric measurements, on the basis of which the values are determined. Patient’s blood serum is analyzed for: erythrocyte count, ×1012/l; total bilirubin level, mcmol/l; albumin level, g/l; INR level. By means of bioimpedance analysis of human body composition the following is determined: phase angle (PA), degrees; fat-free body weight (FFBW), kg; fraction (%) of active cell mass (ACM), defined as percentage of ACM in FFBW, % ACM = (100 × ACM / FFBW)%. By means of anthropometric measurements: fat deposition index (FDI) is determined as: FDI = hip girth, cm/body length, m. Obtained values of seven parameters are assigned with points: if FDI is less than 27.9, 2 points are assigned, FDI 28 and more: 4 points; if there is a share of ACM of 50% or more, 2 points are assigned, share of ACM 49% and less: 4 points; in the presence of PA 6° and more are assigned 2 points, with PA 5° and less: 4 points; in the presence of an erythrocyte count of 4.1 × 1012/l and more are assigned 2 points, 4.0 × 1012/l and less: 4 points; in the presence of total bilirubin from the range of values of 30 and less mcmol/l, 2 points are assigned, from range of 31–60 mcmol/l: 4 points, if value is 61 and more mcmol/l: 6 points; if the albumin level is 35 g/l and more, 3 points are assigned, if value is 34 g/l and less: 6 points; if the INR level is 1.2 or less, 2 points are assigned, and if value is 1.3 or more, 4 points are assigned. Obtained points are summed up. Prognosis of developing ascites within a year in cirrhosis (P) is determined by formula: P=∑Fi /32*100%, where ∑Fi is the sum of points for each indicator, i = from 1 to 7. If the P value is 66% or less, the minimum risk of developing ascites is predicted for a year in cirrhosis, while the P value of 67% and more shows a high risk.
EFFECT: method enables predicting the development of ascites for a year in liver cirrhosis based on taking into account a complex of diagnostically significant parameters - data of bioimpedance analysis of body composition and laboratory data of the patient.
1 cl, 5 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR DIAGNOSING SEVERITY OF LIVER CIRRHOSIS USING BIOIMPEDANCE ANALYSIS DATA | 2024 |
|
RU2830445C1 |
METHOD OF PREDICTING AN INCREASED RISK OF DECOMPENSATION OF LIVER CIRRHOSIS OR THE DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH LIVER CIRRHOSIS IN THE OUTCOME OF CHRONIC HEPATITIS C AFTER ACHIEVING A SUSTAINED VIROLOGIC RESPONSE | 2022 |
|
RU2800251C1 |
METHOD FOR PREDICTION OF FATAL OUTCOME IN PATIENTS SUFFERING FROM VIRAL AND ALCOHOLIC HEPATIC CIRRHOSIS | 2008 |
|
RU2373533C1 |
METHOD FOR PREOPERATIVE PREDICTION OF POST-RESECTION LIVER FAILURE | 2015 |
|
RU2609730C1 |
METHOD OF POSTOPERATIVE PREDICTION OF POST-RESECTION LIVER FAILURE | 2015 |
|
RU2609731C1 |
METHOD FOR QUANTITATIVE ESTIMATION OF SEVERITY OF ALCOHOLIC CIRRHOSIS AND PREDICTION OF FATALITY DURING CURRENT HOSPITALISATION | 2020 |
|
RU2747771C1 |
METHOD FOR ASSESSING RISK OF UNFAVOURABLE OUTCOME FOR PATIENT WITH CIRRHOSIS ON LIVER TRANSPLANTATION WAITING LIST | 2020 |
|
RU2737582C1 |
METHOD FOR ASSESSING THE RISK OF DEATH IN LIVER CIRRHOSIS | 2021 |
|
RU2761729C1 |
METHOD OF PREDICTING DEVELOPMENT OF CRITICAL HEPATIC FAILURE BASING ON SELENIUM LEVEL IN SERUM | 2014 |
|
RU2549963C1 |
METHOD FOR POST-RESECTION LIVER FAILURE PREDICTION IN EARLY POSTOPERATIVE PERIOD | 2016 |
|
RU2610694C1 |
Authors
Dates
2025-05-13—Published
2024-06-04—Filed